Lawyers, Patients Consider Rejecting Court Offer In Hepatitis C Infection Cases (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japanese patients infected with hepatitis C as a result of transfusions of tainted blood plan to reject any out-of-court settlement if it fails to hold the government and drug makers accountable in all of the 200 suits filed so far. Patients and their lawyers were concerned the settlement to be offered by the high court Dec. 13 will hold the parties accountable only in some cases and not others. The court proposal would only urge the defendants to provide financial aid to those affected early, offer varying compensation and exclude some of the patients altogether. (Click here for more ) "Hepatitis C Victims May Reject Settlement Talks" Japan Times (12/10/07)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.